Jiangsu Hengrui Medicine Earnings Seen Weighed by Costs, Lower Sales -- Market Talk
Dow Jones
Oct 30
0600 GMT - HSBC cuts earnings forecasts for Jiangsu Hengrui Medicine for 2025-2027 by 2%-5%, weighed by lower sales and higher costs. Product sales for 2025-2027 are seen weaker due to intensive domestic competition, while selling and administrative expenses are seen rising to support new drug launches. However, HSBC keeps revenue estimates for the same period unchanged, with higher business development revenue from strong product pipeline offsetting weaker product sales. HSBC lowers the stock's target price to CNY77.00 from CNY79.00 but maintains a buy rating as it remains optimistic on Hengrui's long-term growth outlook. The A-shares were last at CNY63.63. (jason.chau@wsj.com)
(END) Dow Jones Newswires
October 30, 2025 02:00 ET (06:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.